Aplasia cutis congenita after methimazole exposure in utero

E. Karg, Edit Bereg, Laszlo Gaspar, M. Katona, S. Túri

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

We describe a patient who was exposed to the antithyroid drug methimazole during the first 6 weeks of gestation and was born prematurely with scalp and skull defects associated with facial asymmetry. A review of the literature seems to support the hypothesis that methimazole is a potential teratogen. Although the risk of birth defects is low with clinically applied doses of the drug, it cannot be regarded as safe and should therefore be avoided in the treatment of pregnant women.

Original languageEnglish
Pages (from-to)491-494
Number of pages4
JournalPediatric Dermatology
Volume21
Issue number4
DOIs
Publication statusPublished - Jul 2004

Fingerprint

Ectodermal Dysplasia
Methimazole
Facial Asymmetry
Teratogens
Antithyroid Agents
Scalp
Skull
Pregnant Women
Pregnancy
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Dermatology
  • Pediatrics, Perinatology, and Child Health

Cite this

Aplasia cutis congenita after methimazole exposure in utero. / Karg, E.; Bereg, Edit; Gaspar, Laszlo; Katona, M.; Túri, S.

In: Pediatric Dermatology, Vol. 21, No. 4, 07.2004, p. 491-494.

Research output: Contribution to journalArticle

Karg, E. ; Bereg, Edit ; Gaspar, Laszlo ; Katona, M. ; Túri, S. / Aplasia cutis congenita after methimazole exposure in utero. In: Pediatric Dermatology. 2004 ; Vol. 21, No. 4. pp. 491-494.
@article{6be16c3a47ed4e1faa95debec9756236,
title = "Aplasia cutis congenita after methimazole exposure in utero",
abstract = "We describe a patient who was exposed to the antithyroid drug methimazole during the first 6 weeks of gestation and was born prematurely with scalp and skull defects associated with facial asymmetry. A review of the literature seems to support the hypothesis that methimazole is a potential teratogen. Although the risk of birth defects is low with clinically applied doses of the drug, it cannot be regarded as safe and should therefore be avoided in the treatment of pregnant women.",
author = "E. Karg and Edit Bereg and Laszlo Gaspar and M. Katona and S. T{\'u}ri",
year = "2004",
month = "7",
doi = "10.1111/j.0736-8046.2004.21417.x",
language = "English",
volume = "21",
pages = "491--494",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Aplasia cutis congenita after methimazole exposure in utero

AU - Karg, E.

AU - Bereg, Edit

AU - Gaspar, Laszlo

AU - Katona, M.

AU - Túri, S.

PY - 2004/7

Y1 - 2004/7

N2 - We describe a patient who was exposed to the antithyroid drug methimazole during the first 6 weeks of gestation and was born prematurely with scalp and skull defects associated with facial asymmetry. A review of the literature seems to support the hypothesis that methimazole is a potential teratogen. Although the risk of birth defects is low with clinically applied doses of the drug, it cannot be regarded as safe and should therefore be avoided in the treatment of pregnant women.

AB - We describe a patient who was exposed to the antithyroid drug methimazole during the first 6 weeks of gestation and was born prematurely with scalp and skull defects associated with facial asymmetry. A review of the literature seems to support the hypothesis that methimazole is a potential teratogen. Although the risk of birth defects is low with clinically applied doses of the drug, it cannot be regarded as safe and should therefore be avoided in the treatment of pregnant women.

UR - http://www.scopus.com/inward/record.url?scp=3943086984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3943086984&partnerID=8YFLogxK

U2 - 10.1111/j.0736-8046.2004.21417.x

DO - 10.1111/j.0736-8046.2004.21417.x

M3 - Article

VL - 21

SP - 491

EP - 494

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 4

ER -